Cooperative Agreement U01CA301481
Award Date 3/20/26
Completion Date 2/28/31
Dollars Obligated $1.1M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Cooperative Agreement Award Summary Awarded by the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), MedStar Health Research Institute Inc. received $2,677,863 on July 25, 2025, to develop and test implementation strategies for delivering practical geriatric assessment in community oncology settings. The project addresses a critical gap in cancer care for older adults, who will comprise 75% of the 22.2 million projected U.S. cancer...
- Federal Cooperative Agreement Summary The National Cancer Institute awarded St. Jude Children's Research Hospital Inc. a Cooperative Agreement totaling $1,059,908 under the Cancer Cause and Prevention Research program (CFDA 93.393), effective August 1, 2025 through July 31, 2030. This award supports the St. Jude Lifetime Cohort (SJLIFE) Study, which conducts longitudinal clinical assessment and health outcome monitoring of childhood cancer survivors across the lifespan. The study addresses...
- Cooperative Agreement Award Summary Cornell University received a $413,509 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective August 4, 2025, through July 31, 2028. The award funds development of a deep learning-based 3D network biology knowledge portal to advance precision oncology. The primary deliverable is the PIONEER (Protein-Protein Interaction Interface Prediction) pipeline, a big-data-driven deep...
- Federal Cooperative Agreement Summary New York University School of Medicine received a $703,423 Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective September 1, 2025 through August 31, 2030. This prospective study examines circulating autoantibodies (AAbs) as biomarkers for breast cancer risk within the NYU Women's Health Study, a cohort of 14,274 women enrolled between 1985 and 1991. The research...
- Federal Grant Award Summary Weill Medical College of Cornell University received a $1,006,599 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2029. This award supports the expansion of NCI-sponsored clinical research in hematologic malignancies to Brooklyn and Queens through the Meyer Cancer Center (MCC) at Weill Cornell Medicine and NewYork-Presbyterian. The project...
- COOPERATIVE AGREEMENT SUMMARY The University of Pennsylvania's Abramson Cancer Center (ACC) received a $368,701 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective April 20, 2026, through February 29, 2032. This award supports the ACC's Lead Academic Participating Sites (LAPS) initiative, which serves as a centralized hub for the NCI's National Clinical Trials Network (NCTN). Under the direction of Principal...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded $941,798 to Beckman Research Institute of the City of Hope under the Cancer Biology Research program (CFDA 93.396) on August 6, 2025, for a five-year initiative concluding July 31, 2030. This cooperative agreement supports fundamental research investigating the mechanism and therapeutic implications of RNA-modification-mediated codon-biased translation in acute myeloid leukemia (AML). The research focuses on...
- Federal Cooperative Agreement Summary The University of Chicago received a $1,368,982 Cooperative Agreement award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective May 1, 2025 through April 30, 2030. The award supports development of a non-invasive blood-based diagnostic tool for early detection of prostate, lung, colorectal, and ovarian cancers. The research leverages the 5-hydroxymethylcytosine-selective exonuclease...
- Federal Cooperative Agreement Summary Kaiser Foundation Hospitals, through its Kaiser Foundation Research Institute, received a $1.4 million Cooperative Agreement from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) awarded September 8, 2025, with completion scheduled for August 31, 2027. This two-phase cooperative agreement supports the adaptation and implementation of an evidence-based patient navigation intervention designed to...
- Federal Grant Award Summary The National Cancer Institute awarded Ann & Robert H Lurie Children's Hospital of Chicago $651,859 under the Cancer Cause and Prevention Research program (CFDA 93.393) on September 19, 2025, for a project extending through August 31, 2030. The award funds development and evaluation of #AYAOSM (The AYA Oncology Self-Care Movement), an influencer-driven social media intervention designed to improve oral chemotherapy adherence among adolescents and young adults...